ISPO

Radiopharmaceutical and pharmaceuticals for the cure of prostate cancer

S Shukla, D. Sc.a,b, R. Cusumano, MD c, G. Atzei MD a, G. Argirò, MD a, S. Boemi MD a, G. Politano MD a, P. Iannantuono MD a, C. Cipriani MD a, F. Petrucci PhD d, A. Alimonti PhD d, S. Caroli PhD d, M. Sinibaldi, PhD b

a Department of Nuclear Medicine, Ospedale S. Eugenio, Roma, Roma Italy b Institute of Chromatography CNR Roma, Roma Italy c Department of Urology, Aurelia Hospital, Roma Italy d Laboratory of Applied Toxicology, ISS Rma Italy

AIM: The aim of our research was to develop radiopharmaceuticals and pharmaceuticals for the cure of prostate cancer because - excepting temporary pain palliation with some radiopharmaceuticals (Sr-89 chloride, Sm-153 EDTMP, or Re-186 HEDP) - there exists no agent to arrest the progress of the disease which, despite the pain palliation therapy, progresses and causes painful death. METHODS: For the cure of the prostate carcinoma it is necessary to administer the agents which recognize the primary as well as secondary cancers in the patients. Yttrium-90, III B group radionuclide, has ideal properties (half life 64 h; pure beta emission of 2.27 MeV) for the systemic therapy. Recently we showed also that its total-body distribution can be studied by imaging Bremsstrahlung scintigraphy. The other element is gallium, of IIIA group, whose radionuclide Ga-67 is used for the detection of cancer and its metastases. Unfortunately, this element has no beta- or alpha-emitting radionuclide. Therefore we are trying to study the anticancer properties of its complexes for systemic chemotherapy. RESULTS:Yttrium-90 anionic citrato-complex has given therapeutic effect in 30 patients who became pain free and resumed their daily activity. The hemotoxicity observed in patients after repeated administration of the radiopharmaceutical suggests the use of another more stable complex of this radionuclide. The uptake of gallium citrato-complex in prostate cancer patients has also shown increased concentration in the cancer tissue and needs further studies. CONCLUSIONS:Yttrium-90 and cold gallium have the properties for preparing effective agents for systemic therapy of prostate cancer.

For more information, contact francesco.petrucci@iss.it

Paper presented at the International Symposium on Predictive Oncology and Intervention Strategies; Paris, France; February 9 - 12, 2002; in the section on Novel Therapies, Part 1.

http://www.cancerprev.org/Journal/Issues/26/101/1195/4627